4SC AG (FRA:VSC)
Germany · Delayed Price · Currency is EUR 0.8300
+0.0200 (2.47%)
Last updated: Oct 22, 2025, 8:09 AM CET
4SC AG Company Description
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany and internationally.
The company develops Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma.
It also out-licenses and partnered drug candidates to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
4SC AG
| Country | Germany |
| Founded | 1997 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 13 |
| CEO | Jason Loveridge |
Contact Details
Address: Fraunhoferstrasse 22 Planegg, 82152 Germany | |
| Phone | 49 89 700 763 0 |
| Website | 4sc.com |
Stock Details
| Ticker Symbol | VSC |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jason Loveridge | Chief Executive Officer |
| Kathleen Masch-Wiest | Chief Operating Officer |